Skip to main content
Journal cover image

International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.

Publication ,  Journal Article
Burris, TP; de Vera, IMS; Cote, I; Flaveny, CA; Wanninayake, US; Chatterjee, A; Walker, JK; Steinauer, N; Zhang, J; Coons, LA; Korach, KS ...
Published in: Pharmacol Rev
November 2023

The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in a wide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight how defective NR signaling results in various diseases and disorders and how NRs can be targeted for therapeutic intervention via modulation via binding to synthetic lipophilic ligands. Furthermore, we also review recent studies that improved our understanding of NR structure and signaling. SIGNIFICANCE STATEMENT: Nuclear receptors (NRs) are ligand-regulated transcription factors that are critical regulators of myriad physiological processes. NRs serve as receptors for an array of drugs, and in this review, we provide an update on recent research into the roles of these drug targets.

Duke Scholars

Published In

Pharmacol Rev

DOI

EISSN

1521-0081

Publication Date

November 2023

Volume

75

Issue

6

Start / End Page

1233 / 1318

Location

Netherlands

Related Subject Headings

  • Transcription Factors
  • Receptors, Cytoplasmic and Nuclear
  • Pharmacology, Clinical
  • Pharmacology & Pharmacy
  • Ligands
  • Humans
  • Carrier Proteins
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Burris, T. P., de Vera, I. M. S., Cote, I., Flaveny, C. A., Wanninayake, U. S., Chatterjee, A., … Cidlowski, J. A. (2023). International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev, 75(6), 1233–1318. https://doi.org/10.1124/pharmrev.121.000436
Burris, Thomas P., Ian Mitchelle S. de Vera, Isabelle Cote, Colin A. Flaveny, Udayanga S. Wanninayake, Arindam Chatterjee, John K. Walker, et al. “International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.Pharmacol Rev 75, no. 6 (November 2023): 1233–1318. https://doi.org/10.1124/pharmrev.121.000436.
Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, et al. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev. 2023 Nov;75(6):1233–318.
Burris, Thomas P., et al. “International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.Pharmacol Rev, vol. 75, no. 6, Nov. 2023, pp. 1233–318. Pubmed, doi:10.1124/pharmrev.121.000436.
Burris TP, de Vera IMS, Cote I, Flaveny CA, Wanninayake US, Chatterjee A, Walker JK, Steinauer N, Zhang J, Coons LA, Korach KS, Cain DW, Hollenberg AN, Webb P, Forrest D, Jetten AM, Edwards DP, Grimm SL, Hartig S, Lange CA, Richer JK, Sartorius CA, Tetel M, Billon C, Elgendy B, Hegazy L, Griffett K, Peinetti N, Burnstein KL, Hughes TS, Sitaula S, Stayrook KR, Culver A, Murray MH, Finck BN, Cidlowski JA. International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023. Pharmacol Rev. 2023 Nov;75(6):1233–1318.
Journal cover image

Published In

Pharmacol Rev

DOI

EISSN

1521-0081

Publication Date

November 2023

Volume

75

Issue

6

Start / End Page

1233 / 1318

Location

Netherlands

Related Subject Headings

  • Transcription Factors
  • Receptors, Cytoplasmic and Nuclear
  • Pharmacology, Clinical
  • Pharmacology & Pharmacy
  • Ligands
  • Humans
  • Carrier Proteins
  • 3214 Pharmacology and pharmaceutical sciences
  • 1115 Pharmacology and Pharmaceutical Sciences